Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars

From the College  |  April 6, 2024

On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.

Filed under:InsuranceLegislation & Advocacy Tagged with:Biosimilarsdrug pricing

ACR Advocates with Payers Against Insufficient Reimbursement for Biosimilars

From the College  |  November 16, 2023

The ACR is engaging with payers regarding formulary requirements that would leave practices underwater when treating patients with rheumatic diseases.

Filed under:Billing/CodingLegislation & Advocacy Tagged with:infliximab biosimilarReimbursement

When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect

Lara C. Pullen, PhD  |  March 22, 2021

In a recent study, researchers designed an intervention centered on communication and led by nurses to address discontinuation rates among patients who had switched to a biosimilar. The nurses’ insight and experience reduced the nocebo effect during the intervention, which had an 84% retention rate for patients taking a biosimilar after one year.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & Biosimilarsinfliximabinfliximab-abdanon-medical switchingRenflexis (infliximab-abda)

New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment

Michele B. Kaufman, PharmD, BCGP  |  March 17, 2021

Clinical trials of biosimilar treatments, including a phase 1 study of SB17, which is biosimilar to ustekinumab, and two phase 3 studies investigating of SB16, which is biosimilar to denosumab, are currently recruiting.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsclinical trialsdenosumabSB17ustekinumab

UHC Updates Rituximab Policy to Require Use of Biosimilars

From the College  |  October 19, 2020

As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.

Filed under:Billing/Coding Tagged with:biosimilar substitutionsnon-medical switchingprior authorizationrituximabrituximab-abbsUnitedHealthCare (UHC)

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Filed under:Biologics/DMARDsResearch Rheum Tagged with:Arthritis & Rheumatologydrug costsinfliximab

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

Allison Martell & Allison Lampert  |  May 29, 2019

TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsBiologics & BiosimilarsBiosimilarsCanada

Biosimilars: How Do They Affect Patient Care & Safety?

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetingadalimumab-attoetanercept-szzsfilgrastim-sndzinfliximab-abdainfliximab-dyyb

The Science Behind Biosimilars

Arthritis & Rheumatology  |  February 27, 2018

Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyBiologics & BiosimilarsBiosimilarsResearch

Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars

From the College  |  February 16, 2018

Several major health plans have recently enacted policies regarding coverage status for Remicade (infliximab) and its biosimilars, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda). Most of these plans are limiting coverage for the biosimilar products to very specific circumstances. Some have also begun denying claims for biosimilars and instructing patients to switch to Remicade. The plans implementing…

Filed under:Biologics/DMARDsFrom the CollegePractice Support Tagged with:Blue CrossBlue ShieldCigna Corp.Humana Inc.INFLECTRA (infliximab-dyyb)REMICADE (infliximab)Renflexis (infliximab-abda)United Healthcare

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 31
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences